Archeus Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Archeus Technologies is a preclinical radiopharmaceutical company with a leadership team combining deep expertise in medical physics, clinical oncology, radiochemistry, and business development. The company is developing a pipeline of small-molecule RPTs and companion diagnostics with curative intent for difficult cancers. While still in preclinical development and pre-revenue, its strong academic ties and experienced leadership position it to advance its targeted agents into human clinical trials.

Oncology

Technology Platform

Development of novel small-molecule radiopharmaceutical therapies (RPT) and paired companion diagnostics for a theranostic approach to target hard-to-treat cancers.

Opportunities

The radiopharmaceutical market is rapidly expanding with high unmet need in hard-to-treat cancers.

Archeus's focus on novel targets and a curative intent positions it to capture value in niche oncology indications with potential for premium pricing.

Its theranostic approach aligns with the precision medicine trend, enabling better patient selection.

Risk Factors

The company faces high preclinical scientific risk, as its novel agents are unproven in humans.

It operates in an increasingly competitive radiopharma landscape against large, well-resourced players.

As a pre-revenue private company, it is dependent on raising capital in a challenging funding environment.

Competitive Landscape

Archeus competes in the radiopharmaceutical sector with giants like Novartis (Pluvicto, Lutathera) and Bayer (Xofigo), as well as numerous biotechs such as RayzeBio, Fusion Pharmaceuticals, and Perspective Therapeutics. Differentiation hinges on discovering novel cancer targets and demonstrating superior efficacy or safety in clinical trials.

More companies in Radiopharmaceuticals →More companies in United States →